Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.18/8073 |
Resumo: | (This article belongs to the Special Issue Compounds from Marine Sources as Hits and Leads for Pharmaceutical, Cosmeceutical and Industrial Applications) |
id |
RCAP_fd69dd7ef93a0dfcc07f04e1b4d2ca15 |
---|---|
oai_identifier_str |
oai:repositorio.insa.pt:10400.18/8073 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell CulturesCisplatinCombinatorial TherapyDoxorubicinFucoxanthinSeaweed CompoundsTriple-Negative Breast Cancer(This article belongs to the Special Issue Compounds from Marine Sources as Hits and Leads for Pharmaceutical, Cosmeceutical and Industrial Applications)Fucoxanthin (Fx) is a carotenoid derived from marine organisms that exhibits anticancer activities. However, its role as a potential drug adjuvant in breast cancer (BC) treatment is still poorly explored. Firstly, this study investigated the cytotoxic effects of Fx alone and combined with doxorubicin (Dox) and cisplatin (Cis) on a panel of 2D-cultured BC cell lines (MCF7, SKBR3 and MDA-MB-231) and one non-tumoral cell line (MCF12A). Fucoxanthin induced cytotoxicity against all the cell lines and potentiated Dox cytotoxic effects towards the SKBR3 and MDA-MB-231 cells. The combination triggering the highest cytotoxicity (Fx 10 µM + Dox 1 µM in MDA-MB-231) additionally showed significant induction of cell death and genotoxic effects, relative to control. In sequence, the same combination was tested on 3D cultures using a multi-endpoint approach involving bioactivity assays and microscopy techniques. Similar to 2D cultures, the combination of Fx and Dox showed higher cytotoxic effects on 3D cultures compared to the isolated compounds. Furthermore, this combination increased the number of apoptotic cells, decreased cell proliferation, and caused structural and ultrastructural damages on the 3D models. Overall, our findings suggest Fx has potential to become an adjuvant for Dox chemotherapy regimens in BC treatment.The Strategic Funding UIDB/04423/2020 and UIDP/04423/2020 partially supported this research, through national funds provided by FCT and ERDF to CIIMAR/CIMAR, in the framework of the program PT2020. The Doctoral Program in Biomedical Sciences, of the ICBAS-University of Porto, offered additional funds.MDPIRepositório Científico do Instituto Nacional de SaúdeMalhão, FernandaMacedo, Ana CatarinaCosta, CarlaRocha, EduardoRamos, Alice Abreu2022-07-06T15:56:42Z2021-07-152021-07-15T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/8073engMolecules. 2021 Jul 15;26(14):4288. doi: 10.3390/molecules26144288.1420-304910.3390/molecules26144288info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-20T15:42:24Zoai:repositorio.insa.pt:10400.18/8073Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:42:48.328409Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures |
title |
Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures |
spellingShingle |
Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures Malhão, Fernanda Cisplatin Combinatorial Therapy Doxorubicin Fucoxanthin Seaweed Compounds Triple-Negative Breast Cancer |
title_short |
Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures |
title_full |
Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures |
title_fullStr |
Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures |
title_full_unstemmed |
Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures |
title_sort |
Fucoxanthin Holds Potential to Become a Drug Adjuvant in Breast Cancer Treatment: Evidence from 2D and 3D Cell Cultures |
author |
Malhão, Fernanda |
author_facet |
Malhão, Fernanda Macedo, Ana Catarina Costa, Carla Rocha, Eduardo Ramos, Alice Abreu |
author_role |
author |
author2 |
Macedo, Ana Catarina Costa, Carla Rocha, Eduardo Ramos, Alice Abreu |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Nacional de Saúde |
dc.contributor.author.fl_str_mv |
Malhão, Fernanda Macedo, Ana Catarina Costa, Carla Rocha, Eduardo Ramos, Alice Abreu |
dc.subject.por.fl_str_mv |
Cisplatin Combinatorial Therapy Doxorubicin Fucoxanthin Seaweed Compounds Triple-Negative Breast Cancer |
topic |
Cisplatin Combinatorial Therapy Doxorubicin Fucoxanthin Seaweed Compounds Triple-Negative Breast Cancer |
description |
(This article belongs to the Special Issue Compounds from Marine Sources as Hits and Leads for Pharmaceutical, Cosmeceutical and Industrial Applications) |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-07-15 2021-07-15T00:00:00Z 2022-07-06T15:56:42Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.18/8073 |
url |
http://hdl.handle.net/10400.18/8073 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Molecules. 2021 Jul 15;26(14):4288. doi: 10.3390/molecules26144288. 1420-3049 10.3390/molecules26144288 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132173706461184 |